Prevention of Prostate Cancer

REFERENCES

• Miller GJ. Prostate cancer among the Chinese: Patho-logic, epidemiologic and nutritional considerations. In: Resnick and Thompson IM, eds. Advanced therapy of prostate disease. London: BC Decker Inc., 2000: 18–27.
   Google Scholar
• Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982; 29: 611–6.
   PubMed Web of Science ®Google Scholar
• Heber D, Fair WR, Omish D Nutrition and prostate cancer: A monograph from the CAPSURE nutrition project, 2nd edn., January 1998.
   Google Scholar
• Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer: geographical distribution and time trends. Acta Oncol 1991; 30: 133–40.
   Google Scholar
• Morton MS, Griffith SK. How the food we eat may protect your health. Diet Cancer 1998: 1–16.
   Google Scholar
• Gallagher RP, Fleshner N. Prostate cancer: 3. Individual risk factors. CMAJ 1998; 159: 807–13.
   Google Scholar
• Kelloff GJ, Lieberman R, Steele VE, Boone CN, Kopelovitch L, Malone WA, et al. Chemoprevention of prostate cancer: concepts and strategies. Eur Urol 1999; 35: 342–50.
   PubMed Web of Science ®Google Scholar
• Kao GD, Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 2000; 88: 615–9.
   PubMed Web of Science ®Google Scholar
• Meyer F, Bairati I, Fradet Y, Moore L. Dietary energy and nutrients in relation to preclinical prostate cancer. Nutr Cancer 1997; 29: 120–6.
   PubMed Web of Science ®Google Scholar
• Mukherjee P. Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 1999; 91: 512–23.
   Google Scholar
• Whittemore AS, Kolonel LN, Wu AK John EM, Gallagher RP, Howe GR, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995; 87: 652–61.
   Google Scholar
• Rohan TE, Howe GR, Burch JD, Jain M. Dietary factors and risk of prostate cancer: a case-control study in Ontario, Canada. Cancer Causes Control 1995; 6: 145–54.
   PubMed Web of Science ®Google Scholar
• Grönberg H, Damber L, Damber JE. Total food consumption and body mass index in relation to prostate cancer risk: a case-control study in Sweden with prospectively collected exposure data. J Urol 1996; 155: 969–74.
   Google Scholar
• Schuurman AG, van den Brandt PA, Dorant E, Brants HA, Goldbohm RA. Association of energy and fat intake with prostate carcinoma risk: Results from the Nether-lands Cohort Study. Cancer 1998; 86: 1019–27.
   Web of Science ®Google Scholar
• Montironi R, Mazzucchelli R, Marshall JR, Bartels PH. Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents. J Clin Pathol 1999; 52: 793–803.
   PubMed Web of Science ®Google Scholar
• Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L. Dietary fat and prostate cancer survival. Cancer Causes Control 1999; 10: 245–51.
   PubMed Web of Science ®Google Scholar
• Brawley OW, Knopf K, Thompson IM. Epidemiology of prostate cancer. Part II: the risk factors. Semin Urol Oncol 1998; 16: 193–201.
   Web of Science ®Google Scholar
• Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: current status. J Natl Cancer Inst 1999; 91: 414–28.
   PubMedGoogle Scholar
• Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993; 85: 1571–9.
   PubMed Web of Science ®Google Scholar
• Pandali PK, Pilat MJ, Yamazaki K, Naik H, Pienta KJ. The effects of Omega-3 and Omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res 1996; 16: 815–20.
   Google Scholar
• Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE, Vatten L. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer 1997; 71: 545–51.
   PubMed Web of Science ®Google Scholar
• Norrish AE, Ferguson LR, Knize MG, Felton JS, Sharpe SJ, Jackson RT. Heterocyclic amine content of cooked meat and risk of prostate cancer. J Natl Cancer Inst 1999; 91: 2038–44.
   PubMed Web of Science ®Google Scholar
• Krinsky NI. Overview of lycopene, carotenoids and disease prevention. Proc Soc Exp Biol Med 1998; 218: 95–7.
   PubMed Web of Science ®Google Scholar
• Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A, et al. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 2000; 36: 101–11.
   PubMed Web of Science ®Google Scholar
• Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM. Prostate cancer and dietary carotenoids. Am J Epidemiol 2000; 151: 119–23.
   PubMed Web of Science ®Google Scholar
• Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999; 59: 1225–30.
   PubMed Web of Science ®Google Scholar
• Cook NR, Stampfer MJ, Ma J, Manson JE, Sacks FM, Buring JE, et al. Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer 1999; 86: 1783–92.
   PubMed Web of Science ®Google Scholar
• Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999; 91: 317–31.
   PubMed Web of Science ®Google Scholar
• Eichholzer M. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17 years of follow-up of the prospective based study. Int J Cancer 1996; 66: 145–50.
   PubMed Web of Science ®Google Scholar
• Fair WR, Fleshner NE, Heston W. Cancer of the prostate: a nutritional disease? Urology 1997; 50: 840–8.
   Google Scholar
• Peto R, Doll R, Buckley JB, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature 1981; 290: 201–8.
   PubMed Web of Science ®Google Scholar
• Machlin LJ, Bendich A. Free radical tissue damage: protective role of antioxidant nutrients. FASEB J 1987; 1: 441–5.
   PubMed Web of Science ®Google Scholar
• Whelan P. Retinoids in chemoprevention. Eur Urol 1999; 35: 424–8.
   PubMed Web of Science ®Google Scholar
• Heinonen OP, Albanes D, Virtano J, Huttunen JK, Taylor PR, Hartman AM. Prostate cancer and supple-mentation with oc-tocopherol and fl-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998; 90: 440–6.
   PubMed Web of Science ®Google Scholar
• Moyad MA, Brumfield SK, Pienta KJ. Vitamin E, alpha-and gamma-tocopherol, and prostate cancer. Semin Urol Oncol 1999; 17: 85–90.
   PubMedGoogle Scholar
• Bonn D. Vitamin E may reduce prostate cancer incidence. Lancet 1998; 351: 961.
   PubMed Web of Science ®Google Scholar
• Fleshner N, Fair WR, Huryk R, Heston WD. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol 1999; 161: 1651–4.
   PubMed Web of Science ®Google Scholar
• Israel K, Yu W, Sanders BG, Kline K. Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer 2000; 36: 90–100.
   PubMed Web of Science ®Google Scholar
• Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prey 1999; 8: 893–9.
   PubMed Web of Science ®Google Scholar
• Hanchette CL, Schwarz GG. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer 1992; 70: 2861–9.
   PubMed Web of Science ®Google Scholar
• Chen TC, Schwartz GG, Bumstein KL, Lokeshwar BL, Bolick MF. The in vitro evaluation of 25-hydroxyvita-mM D3 and 19-nor-lalpha, 25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res 2000; 6: 901–8.
   Google Scholar
• Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000; 60: 305–8.
   PubMed Web of Science ®Google Scholar
• Liman P. Grönberg H, Matsuyama H, Kivineva M, Bergerheim US, Li C. Links between genetic and environmental factors and prostate cancer risk. Prostate 1999; 39: 262–8.
   Google Scholar
• Kibel AS, Isaacs SD, Isaacs WB, Bova GS. Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol 1998; 160: 1405–9.
   PubMed Web of Science ®Google Scholar
• Peehl DM. Vitamin D and prostate cancer risk. Eur Urol 1999; 35: 392–4.
   PubMed Web of Science ®Google Scholar
• Konety BR, Johnson CS, Trump DL, Getzenberg RH. Vitamin D in the prevention and treatment of prostate cancer. Semin Urol Oncol 1999; 17: 77–84.
   PubMedGoogle Scholar
• Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000; 92: 61–8.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998; 58: 442–7.
   PubMed Web of Science ®Google Scholar
• Giovannucci E. Calcium and milk and prostate cancer: A review of the evidence. Prostate J 1999; 1: 1–7.
   Google Scholar
• Xue L, Lipkin M, Newmark H, Wang J. Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice. J Natl Cancer Inst 1999; 91: 176–81.
   PubMedGoogle Scholar
• Yip I, Heber D, Aronson W. Nutrition and prostate cancer. Urol Clin N Am 1999; 26: 403–11.
   PubMed Web of Science ®Google Scholar
• Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull EW, Slate EH, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998; 81: 730–4.
   Google Scholar
• Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998; 90: 1219–24.
   PubMed Web of Science ®Google Scholar
• Bylund A, Zhang IX, Bergh A, Damber JE, Widmark A, Johansson A, et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate 2000; 42: 304–14.
   PubMed Web of Science ®Google Scholar
• Landstrom M, Zhang JX, Hallmans G, Aman P. Bergh A, Damber JE, et al. Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate 1998; 36: 151–61.
   PubMed Web of Science ®Google Scholar
• Yang Z, Liu S, Chen X, Chen H, Huang M, Zheng J. Induction of apoptotic cell death and in vivo growth inhibition of human cancer cells by a saturated branched-chain fatty acid, 13-methyltetradecanoic acid. Cancer Res 2000; 60: 505–9.
   PubMed Web of Science ®Google Scholar
• Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, Sarkar FH. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol 2000; 16: 1091–7.
   PubMed Web of Science ®Google Scholar
• Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 1998; 90: 1637–47.
   PubMed Web of Science ®Google Scholar
• Montironi R, Schulman CC. Precursors of prostatic cancer: progression, regression and chemoprevention. Eur Urol 1996; 30: 33–7.
   Web of Science ®Google Scholar
• Schröder FH, Kranse R, Dijk MA, Blom MJ, Tijburg LM, Westrate JA, et al. Tertiary prevention of prostate cancer by dietary intervention: results of a randomized, double blind, placebo controlled, cross-over study. Eur Urol 2000; 37\(Suppl 2): A96.
   Google Scholar
• Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neopla-sia of the prostate in young male patients. J Urol 1993; 150: 379–85.
   Google Scholar
• Kelloff GJ, Boone CW, Crowell JA, et al. Surrogate endpoint biomarkers for phase II cancer chemopreven-tion trials. J Cell Biochem 1994; 19(Suppl): 1–9.
   Google Scholar
• Bostwick DG, Neumann R, Qian J, Cheng L. Reversi-bility of prostatic intraepithelial neoplasia: implications for chemoprevention. Eur Urol; 35: 492–5.
   Google Scholar
• Demark-Wahnefried W, Peterson B, McBride C, Lipkus I, Clipp E. Current health behaviors and readiness to pursue life-style changes among men and women diagnosed with early stage prostate and breast carcino-mas. Cancer 2000; 88: 674–84.
   Google Scholar
• Thompson IA, Coltman CA. Chemoprevention of cancer of the prostate. In: Resnick MI, Thompson IM, ed. Advanced therapy of prostate disease. London: BC Decker Inc., 2000: 428–445.
   Google Scholar
• Denis L, Morton MS, Griffiths K. Diet and its preventive role in prostate disease. Eur Urol 1999; 35: 377–87.
   Google Scholar